论文部分内容阅读
目的 :评价肿瘤标记物CYFRA2 1- 1、NSE对肺癌诊断和预测预后的价值。方法 :将肺癌患者分为非小细胞性肺癌组 (NSCLC)和小细胞性肺癌组 (SCLC) ,良性疾病患者为对照组。采静脉血 ,按RIA方法检测CYFRA2 1- 1、NSE。采用STATA统计软件进行结果分析。结果 :CYFRA2 1- 1水平在NSCLC中明显高于SCLC和良性疾病患者 ,分别为 15 .45± 4.0 1、6.14± 3 .88、1.86± 0 .89。NSE则在SCLC中显著高于NSCLC和良性疾病组 ,分别为 3 .90± 1.47、2 .65± 1.47、2 .16± 0 .74。CYFRA2 1- 1、NSE联合检测与各单项指标相比 ,正确率增高 (P <0 .0 1) ,而且NSE是提示SCLC预后的有价值的指标 ,CYFRA2 1- 1则是提示NSCLC预后的有价值的指标。结论 :联合检测血清中CYFRA2 1- 1、NSE的含量诊断肺癌的阳性率最高 ,准确性达 87.41% ,同时显示 ,NSE、CYFRA2 1- 1分别是提示SCLC、NSCLC预后的有价值的独立指标 ,在临床上有重要的应用价值
Objective: To evaluate the value of tumor marker CYFRA2 1- 1 and NSE in the diagnosis and prognosis of lung cancer. Methods: Patients with lung cancer were divided into non-small cell lung cancer group (NSCLC) and small cell lung cancer group (SCLC), benign disease patients as control group. Venous blood was collected and tested for CYFRA2 1- 1, NSE by RIA method. Using STATA statistical software for analysis of results. Results: The level of CYFRA2 1- 1 in NSCLC was significantly higher than that in patients with SCLC and benign diseases, which were 15.45 ± 4.0, 1.64 ± 3.88 and 1.86 ± 0.89, respectively. NSE was significantly higher in SCLC than in NSCLC and benign disease groups, which were 3.90 ± 1.47, 2.65 ± 1.47 and 2.16 ± 0.74, respectively. The positive rate of CYFRA2 1- 1 and NSE combined test was higher than that of each single index (P <0.01), and NSE was a valuable index to predict the prognosis of SCLC. CYFRA2 1- 1 was the prognostic indicator of NSCLC The value of the indicator. Conclusion: The positive rate of CYFRA21-1 and NSE in the diagnosis of lung cancer detected by combined detection is the highest, with an accuracy of 87.41%. Meanwhile, NSE and CYFRA2 1- 1 are valuable independent prognostic indicators for SCLC and NSCLC, respectively. In clinical practice has important application value